The study results were derived after the company excluded data from
four patients who showed an extreme response to the placebo, Alcobra
said in a statement.
The company said the study scored the drug, Metadoxine, on the same
scale used in studies that evaluated other attention deficit
hyperactivity disorder, or ADHD, drugs.
(Reporting by Vidya L Nathan in Bangalore; Editing by Savio D'Souza)
[to top of second column]
[© 2014 Thomson Reuters. All rights
Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.